At the Alzheimer’s Association International Conference® 2015 (AAIC®), Jeff Sevigny, M.D., senior director of clinical development at Biogen Idec, talks about findings from PRIME, the Phase 1b study of the experimental drug aducanumab.
Latest article
Take it from the rats: A junk food diet can cause long-term damage to...
A new USC-led study on rats that feasted on a high-fat, sugary diet raises the possibility that a junk food-filled diet in teens may...
Repurposing non-pharmacological interventions for Alzheimer’s disease through link prediction on biomedical literature
The complete workflow is depicted in Fig. 1. To investigate the association between NPIs and AD, we initially conducted preprocessing and integration of biomedical triples...
Degenerative Dementias and Their Medical Care in the Movies
Compared with other neurologic problems, few films have been dedicated to degenerative dementia. To our knowledge, this is the first systematic review about the...
